{
     "PMID": "28286213",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20170905",
     "LR": "20170906",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "118",
     "DP": "2017 May 15",
     "TI": "Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus.",
     "PG": "148-156",
     "LID": "S0028-3908(17)30092-8 [pii] 10.1016/j.neuropharm.2017.03.009 [doi]",
     "AB": "Rats injected with by d-phenylalanine, a carbonic anhydrase (CA) activator, enhanced spatial learning, whereas rats given acetazolamide, a CA inhibitor, exhibited impairments of fear memory consolidation. However, the related mechanisms are unclear. We investigated if CAs are involved in a non-spatial recognition memory task assessed using the object recognition test (ORT). Systemic administration of acetazolamide to male CD1 mice caused amnesia in the ORT and reduced CA activity in brain homogenates, while treatment with d-phenylalanine enhanced memory and increased CA activity. We provided also the first evidence that d-phenylalanine administration rapidly activated extracellular signal-regulated kinase (ERK) pathways, a critical step for memory formation, in the cortex and the hippocampus, two brain areas involved in memory processing. Effects elicited by d-phenylalanine were completely blunted by co-administration of acetazolamide, but not of 1-N-(4-sulfamoylphenyl-ethyl)-2,4,6-trimethylpyridinium perchlorate ((C18),) a CA inhibitor that, differently from acetazolamide, does not cross the blood brain barrier. Our results strongly suggest that brain but not peripheral CAs activation potentiates memory as a result of ERK pathway enhanced activation.",
     "CI": [
          "Copyright (c) 2017 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Canto de Souza, Lucas",
          "Provensi, Gustavo",
          "Vullo, Daniela",
          "Carta, Fabrizio",
          "Scozzafava, Andrea",
          "Costa, Alessia",
          "Schmidt, Scheila Daiane",
          "Passani, Maria Beatrice",
          "Supuran, Claudiu T",
          "Blandina, Patrizio"
     ],
     "AU": [
          "Canto de Souza L",
          "Provensi G",
          "Vullo D",
          "Carta F",
          "Scozzafava A",
          "Costa A",
          "Schmidt SD",
          "Passani MB",
          "Supuran CT",
          "Blandina P"
     ],
     "AD": "Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Chimica 'Ugo Schiff', Universita degli Studi di Firenze, Sesto Fiorentino, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Chimica 'Ugo Schiff', Universita degli Studi di Firenze, Sesto Fiorentino, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Scienze della Salute, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Universita degli Studi di Firenze, Firenze, Italy. Electronic address: patrizio.blandina@unifi.it.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20170309",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (1-N-(4-sulfamoylphenylethyl)-2,4,6-trimethylpyridinium)",
          "0 (Carbonic Anhydrase Inhibitors)",
          "0 (Pyridinium Compounds)",
          "0 (Sulfonamides)",
          "47E5O17Y3R (Phenylalanine)",
          "EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)",
          "EC 4.2.1.1 (Carbonic Anhydrases)",
          "O3FX965V0I (Acetazolamide)"
     ],
     "SB": "IM",
     "MH": [
          "Acetazolamide/pharmacology",
          "Analysis of Variance",
          "Animals",
          "Carbonic Anhydrase Inhibitors/pharmacology",
          "Carbonic Anhydrases/*metabolism",
          "Cerebral Cortex/drug effects/*enzymology",
          "Dose-Response Relationship, Drug",
          "Drug Administration Routes",
          "Extracellular Signal-Regulated MAP Kinases/*metabolism",
          "Hippocampus/drug effects/*enzymology",
          "Male",
          "Mice",
          "Motor Activity/drug effects",
          "Phenylalanine/pharmacology",
          "Phosphorylation/drug effects",
          "Pyridinium Compounds/pharmacology",
          "Recognition (Psychology)/drug effects/*physiology",
          "Sulfonamides/pharmacology"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "1-N-(4-sulfamoylphenyl-ethyl)-2,4,6-Trimethylpyridinium perchlorate",
          "Acetazolamide",
          "d-phenylalanine"
     ],
     "EDAT": "2017/03/14 06:00",
     "MHDA": "2017/09/07 06:00",
     "CRDT": [
          "2017/03/14 06:00"
     ],
     "PHST": [
          "2016/11/18 00:00 [received]",
          "2017/02/24 00:00 [revised]",
          "2017/03/07 00:00 [accepted]",
          "2017/03/14 06:00 [pubmed]",
          "2017/09/07 06:00 [medline]",
          "2017/03/14 06:00 [entrez]"
     ],
     "AID": [
          "S0028-3908(17)30092-8 [pii]",
          "10.1016/j.neuropharm.2017.03.009 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2017 May 15;118:148-156. doi: 10.1016/j.neuropharm.2017.03.009. Epub 2017 Mar 9.",
     "term": "hippocampus"
}